North America Latent TB Detection Market
North America is the largest market for latent TB detection, with the US holding the largest market share, followed by Canada. High R&D spending primarily drives the growth of this market for new technologies, and the presence of major market players in the US are going to accelerate the growth of this market in this country. The United States continues to have one of the lowest TB case rates in the world, and the 2019 case count represents the lowest number of TB cases on record. However, according to the Centers of Disease Control and Prevention (CDC), there is still a significant percentage of people that suffer from TB and the progress toward eliminating TB is relatively slow in the country. During 2019, the United States reported the lowest number of TB cases (8,916) and lowest incidence rate (2.7 cases per 100,000 persons) since individual TB case reporting began in 1953. This owes to appropriate diagnosis of TB and adoption of latent TB detection methods. In 2019, a total of 71.4% of reported TB cases in the United States occurred among people born outside the United States. Moreover, the US suffers huge economic burden due to the high prevalence of respiratory diseases in the country. The rising number of patients suffering with respiratory disorders and COPD are thus expected to generate the need for latent TB detection kits in the country over the coming years. The growth in North America is characterized by entry of new market players and product launches and rapidly developing healthcare facilities. In addition, rise in the geriatric population and increasing incidences of chronic diseases are further expected stimulate the growth of latent TB detection market in North America.
In case of COVID-19, North America is highly affected specially the US. North America has been witnessing a growing number of COVID-19 cases since its outbreak. As per the CDC, In the US, up to 13 million people may have latent tuberculosis infection. Testing for and treating LTBI is the most effective way to prevent TB infection. Recommended by the CDC, IGRA technology is the required method of TB testing for US Citizenship and Immigration Services (USCIS) immigration exams. The COVID-19 pandemic has threatened the national TB programs worldwide. The WHO have also notified that pandemic is threatening to reverse global progress against tuberculosis. The US is also being affected by the COVID-19 with regards to TB management. CDC’s Division of Tuberculosis Elimination (DTBE) funds 61 state, local, and territorial tuberculosis programs in the US through the TB Elimination and Laboratory cooperative agreement. In April 2020, as part of routine monitoring, CDC communicated with 50 of the 61 (82%) grantees to estimate the effect of COVID-19 on essential TB activities. The observations suggested that the COVID-19 response is diverting resources from essential TB elimination activities. The COVID-19 response has affected multiple sectors of public health, recommended preventive screening, and clinical care in the region. In some TB centers (Mexico), the hospital patient intake system was modified to support COVID-19 admissions, thus severely hindering TB services. In some centers, screening for LTBI was considered a lower priority than screening for COVID-19.
Strategic insights for the North America Latent TB Detection provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
| Report Attribute | Details |
|---|---|
| Market size in 2020 | US$ 513.29 Million |
| Market Size by 2027 | US$ 748.25 Million |
| Global CAGR (2020 - 2027) | 5.5% |
| Historical Data | 2018-2019 |
| Forecast period | 2021-2027 |
| Segments Covered |
By Test
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The geographic scope of the North America Latent TB Detection refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.
The North America latent TB detection market is expected to grow from US$ 513.29 million in 2020 to US$ 748.25 million by 2027; it is estimated to grow at a CAGR of 5.5% from 2020 to 2027. Countries in North America such as Mexico is emerging as attractive outsourcing locations for tuberculosis diagnosis. Countries such as US is among the highest-affected countries with TB. This drives the need for appropriate and advanced diagnostics for TB in developing countries. According to the BMJ Medicine, North America region continues to battle TB as one of the most severe health challenges and does not have sufficient resources for latent TB detection, treatment, and medication facilities. This provides market players with opportunities to build their sustainable bases in the region and tap the unexplored opportunities. Low manufacturing and operating costs offer lucrative opportunities for the growth of diagnostic and therapeutic in the region. Recent growth in the biopharmaceutical industry indicates positive future outlook for the market under study. Moreover, the growing domestic market and its advancement of novel technologies are opening up new avenues for contract manufacturers and diagnostic test manufacturers for latent TB detection in North America region.
In terms of test, the interferon gamma released assay (IGRA) segment accounted for the largest share of the North America latent TB detection market in 2019. In terms of end user, the hospitals segment held a larger market share of the North America latent TB detection market in 2019.
A few major primary and secondary sources referred to for preparing this report on the North America latent TB detection market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Abbott; ARKRAY, Inc.; BD; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Lionex GmbH; Oxford Immunotec Ltd; QIAGEN; and Serum Institute of India Pvt. Ltd.
The North America Latent TB Detection Market is valued at US$ 513.29 Million in 2020, it is projected to reach US$ 748.25 Million by 2027.
As per our report North America Latent TB Detection Market, the market size is valued at US$ 513.29 Million in 2020, projecting it to reach US$ 748.25 Million by 2027. This translates to a CAGR of approximately 5.5% during the forecast period.
The North America Latent TB Detection Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the North America Latent TB Detection Market report:
The North America Latent TB Detection Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The North America Latent TB Detection Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the North America Latent TB Detection Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For North America Latent TB Detection Market
